Covalent cysteine binding drugs have gained renewed interest, since the Food and Drug Administration (FDA) awarded a “breakthrough drug” status to cysteine-directed covalent inhibitors that target Bruton’s tyrosine kinase (BTK) and a drug-resistant EGFR mutant in cancer (26, 28–30). This evidence concerns the gene BTK and cancer.